Alvotech

Alvotech S.A. is a biopharmaceutical company dedicated to the development and manufacture of biosimilar medicines. Its primary function is to enhance the accessibility and affordability of high-quality, complex biologics which are essential in the treatment of various critical conditions. By focusing on biosimilars, Alvotech aims to challenge the status quo of biopharmaceutical manufacturing, potentially lowering healthcare costs and increasing patient access to essential treatments. The company's portfolio predominantly impacts the healthcare sector, specifically concerning biologic medications for autoimmune diseases, oncology treatments, and other specialized therapeutics. Alvotech S.A. undertakes comprehensive research and development activities, achieving milestones through proprietary technologies and expertise in biologics, which encompass production, regulatory, and commercial processes. In the financial markets, Alvotech S.A. represents a critical player in the biosimilars niche, offering investors exposure to the growing demand for biosimilar drugs globally. Headquartered in Reykjavik, Iceland, the company collaborates with a network of partners worldwide to advance its mission, positioning itself as a leader within this innovative and rapidly expanding segment of the pharmaceutical industry.